Journal Article

Clinical Profile of an Atypical Antipsychotic: Risperidone

John M. Davis and Nancy Chen

in Schizophrenia Bulletin

Published on behalf of Maryland Psychiatric Research Center

Volume 28, issue 1, pages 43-61
Published in print January 2002 | ISSN: 0586-7614
Published online January 2002 | e-ISSN: 1745-1701 | DOI:
Clinical Profile of an Atypical Antipsychotic: Risperidone

More Like This

Show all results sharing this subject:

  • Child and Adolescent Psychiatry


Show Summary Details


Stimulated by Dawkins and colleagues' (1999) and Remington and Kapur's (2000) calls to develop clinical profiles of the new atypical antipsychotic drugs and by Mattes's critiques (1997, 1998), we performed two sets of analyses for risperidone. First, we reanalyzed data from the North American risperidone trial: risperidone was superior to haloperidol to an equal degree in patients with and without the deficit syndrome, in patients with paranoid and nonparanoid schizophrenia, in treatment-resistant and treatment-responsive patients (patients hospitalized for longer and shorter periods), and in patients with or without weight gain. Moreover, risperidone was more effective than haloperidol on symptoms nonresponsive and responsive to haloperidol; its effects on negative symptoms were independent of its effects on extrapyramidal symptoms; and it was effective in treating depression in schizophrenia. Second, we performed a meta-analysis of 18 controlled risperidone trials: risperidone was consistently more effective than conventional antipsychotics in treating positive and negative symptoms.

Keywords: Atypical antipsychotics; risperidone; schizophrenia treatment; extrapyramidal side effects

Journal Article.  0 words. 

Subjects: Child and Adolescent Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.